| Company Name: | Ventana Medical Systems, Incorporated | | Ticker Symbol: | VMSI | | | WWW Address: | www.ventanamed.com | | CEO: | Christopher M. Gleeson | | No. of Employees: | 952 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures, and markets instrument-reagent systems that automate slide staining in anatomical pathology and drug discovery laboratories worldwide.
|
| | | Industry Information: | HEALTH SERVICES - Medical Instruments & Supplies [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | |  | - | - | 0 | 89.50 | 89.43 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3,101.3 | 34.7 | 0.30 | 0.87 | 0.00 | 86.9 | 0.0 | 90.25 - 39.14 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 89.47 | $ | | PE Ratio - LTM | 86.9 | |
| Market Capitalisation | 3,101.3 | mil |
| Latest Shares Outstanding | 34.7 | mil |
| Earnings pS (EPS) | 0.87 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 250,234 | $ |
| Effective Tax Rate | 33.6 | % |
| Float | 28.9 | mil |
| Float as % of Shares Outstanding | 83.4 | % |
| Foreign Sales | 67 | mil |
| Domestic Sales | 171 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 43.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 14.00 | % |
| Gross Profit Margin | 81.1 | % |
| EBITDA Margin | 23.7 | % |
| Pre-Tax Profit Margin | 19.6 | % |
| Assets Turnover | 1.0 | % |
| Return on Assets (ROA) | 12.2 | % |
| Return on Equity (ROE) | 17.2 | % |
| Return on Capital Invested (ROCI) | 17.1 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.01 | |
| LT Debt/Total Capital | 1.0 | % |
| Working Capital pS | 1.70 | $ |
| Cash pS | 0.86 | $ |
| Book-Value pS | 6.15 | $ |
| Tangible Book-Value pS | 5.09 | $ |
| Cash Flow pS | 1.61 | $ |
| Free Cash Flow pS | -0.12 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 14.55 | |
| Price/Tangible Book Ratio | 17.58 | |
| Price/Cash Flow | 55.6 | |
| Price/Free Cash Flow | -745.6 | |
| P/E as % of Industry Group | 256.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.3 | 100 | 5,728 | 2,530 |
| 4 Weeks | 89.55 | 88.89 | 88.97 | 0.6 | 98 | 10,257 | 174,365 |
| 13 Weeks | 89.67 | 83.95 | 87.94 | 1.7 | 108 | 7,155 | 422,138 |
| 26 Weeks | 90.25 | 80.72 | 81.93 | 9.2 | 119 | 4,615 | 562,987 |
| 52 Weeks | 90.25 | 39.14 | 42.06 | 112.7 | 227 | 4,847 | 1,206,907 |
| YTD | 89.55 | 84.18 | - | 2.6 | 111 | 10,658 | 362,369 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 89.35 | 89.38 | 87.58 | 85.86 | 79.41 | 0.30 | -0.22 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 20.94 | 99.1 | 17.70 |
| Income | 58.08 | 89.7 | 26.76 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 11.45 | NA | 55.91 |
| R&D | 18.00 | NA | 21.11 |
| Normalized Inc. | 60.87 | NA | 30.82 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 23.1 | 28.4 | 19.6 |
| Earnings % | 25.9 | -96.6 | 23.9 |
| EPS % | 29.1 | -95.5 | 26.1 |
| EPS $ | 0.16 | -0.21 | 0.18 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 45.36 |
| Current Ratio | 3.3 |
| Quick Ratio (Acid Test) | 2.8 |
| Liquidity Ratio (Cash) | 1.92 |
| Receivables Turnover | 5.6 |
| Average Collection Period | 64 |
| Working Capital/Equity | 57.0 |
| Working Capital pS | 3.49 |
| Cash-Flow pS | 1.38 |
| Free Cash-Flow pS | 0.54 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 36.12 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 20.4 |
| Total Debt/Equity (Gearing Ratio) | 0.01 |
| LT Debt/Equity | 0.01 |
| LT Debt/Capital Invested | 1.3 |
| LT Debt/Total Liabilities | 3.8 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 24.34 |
| Tobin's Q Ratio | 11.54 |
| Current P/E Ratio - LTM | 86.90 |
| Enterprise Value (EV)/EBITDA | 49.48 |
| Enterprise Value (EV)/Free Cash Flow | 173.30 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 17.58 |
| Price/Book Ratio - LTM | 14.55 |
| Price/Cash Flow Ratio | 55.6 |
| Price/Free Cash Flow Ratio - LTM | -745.6 |
| Price/Sales Ratio | 11.16 |
| P/E Ratio (1 month ago) - LTM | 82.8 |
| P/E Ratio (26 weeks ago) - LTM | 66.1 |
| P/E Ratio (52 weeks ago) - LTM | 49.5 |
| 5-Y High P/E Ratio | 128.0 |
| 5-Y Low P/E Ratio | 32.5 |
| 5-Y Average P/E Ratio | 72.6 |
| Current P/E Ratio as % of 5-Y Average P/E | 120 |
| P/E as % of Industry Group | 256.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 63.5 |
| PER SHARE FIGURES |
| LT Debt pS | 0.06 |
| Current Liabilities pS | 1.49 |
| Tangible Book Value pS - LTM | 5.09 |
| Book Value pS - LTM | 6.15 |
| Capital Invested pS | 6.23 |
| Cash pS - LTM | 0.86 |
| Cash Flow pS - LTM | 1.61 |
| Free Cash Flow pS - LTM | -0.12 |
| Earnings pS (EPS) | 0.87 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 7.85 |
| Free Cash Flow Margin 5YEAR AVG | 10.06 |
| Net Profit Margin | 13.3 |
| Net Profit Margin - 5YEAR AVRG. | 10.5 |
| Equity Productivity | 1.11 |
| Return on Equity (ROE) | 14.8 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.2 |
| Capital Invested Productivity | 1.10 |
| Return on Capital Invested (ROCI) | 14.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 12.1 |
| Assets Productivity | 1.00 |
| Return on Assets (ROA) | 11.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.7 |
| Gross Profit Margin | 81.1 |
| Gross Profit Margin - 5YEAR AVRG. | 79.9 |
| EBITDA Margin - LTM | 23.7 |
| EBIT Margin - LTM | 19.6 |
| Pre-Tax Profit Margin | 20.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 14.6 |
| Effective Tax Rate | 33.6 |
| Effective Tax Rate - 5YEAR AVRG. | 20.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 200 |
| Revenue per Employee | 250,234 |
| Net Income per Employee | 33,170 |
| Average Collection Period | 72 |
| Receivables Turnover | 5.6 |
| Day's Inventory Turnover Ratio | 128 |
| Inventory Turnover | 2.8 |
| Inventory/Sales | 7.7 |
| Accounts Payble/Sales | 6.56 |
| Assets/Revenue | 1.00 |
| Net Working Capital Turnover | 1.96 |
| Fixed Assets Turnover | 2.52 |
| Total Assets Turnover | 1.0 |
| Revenue per $ Cash | 7.50 |
| Revenue per $ Plant | 3.64 |
| Revenue per $ Common Equity | 1.11 |
| Revenue per $ Capital Invested | 1.10 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 42.3 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 44.1 |
| Research & Devlopment (R&D) as % of Revenue | 13.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 13.4 |
|
|  
|
| |
 |  |